Moving Toward Transparency of Clinical Trials

As new policies promote transparency of clinical trials through registries and results databases, further issues arise and require examination.

[1]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[2]  M. Goodyear,et al.  Learning from the TGN1412 trial , 2006, BMJ : British Medical Journal.

[3]  B. Psaty,et al.  Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis , 2004 .

[4]  S. Thaul,et al.  Clinical Trials Reporting and Publication , 2005 .

[5]  B. Psaty,et al.  Rosiglitazone and cardiovascular risk. , 2007, The New England journal of medicine.

[6]  Drummond Rennie,et al.  Trial registration: a great idea switches from ignored to irresistible. , 2004, JAMA.

[7]  R. Simes.  Publication bias: the case for an international registry of clinical trials. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. G. Palmer,et al.  Institutional review boards should require clinical trial registration. , 2007, Archives of internal medicine.

[9]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[10]  C. Laine.  Postmenopausal Hormone Replacement Therapy: How Could We Have Been So Wrong? , 2002, Annals of Internal Medicine.

[11]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[12]  D. B. Ross.  The FDA and the case of Ketek. , 2007, The New England journal of medicine.

[13]  Ana Marusic,et al.  Clinical trial registration--looking back and moving ahead. , 2007, The New England journal of medicine.

[14]  E. Wager.  Publishing Clinical Trial Results: The Future Beckons , 2006, PLoS clinical trials.

[15]  Bruce M Psaty,et al.  The record on rosiglitazone and the risk of myocardial infarction. , 2007, The New England journal of medicine.

[16]  Celia B. Fisher,et al.  Clinical Trials Results Databases: Unanswered Questions , 2006, Science.

[17]  Nicholas C. Ide,et al.  Issues in the registration of clinical trials. , 2007, JAMA.

[18]  H. Miller,et al.  Governmental influences on drug development: striking a better balance , 2007, Nature Reviews Drug Discovery.

[19]  C. Holden.  FDA Weighs Suicide Risk in Children on Antidepressants , 2004, Science.

[20]  C. Rosen.  The rosiglitazone story--lessons from an FDA Advisory Committee meeting. , 2007, The New England journal of medicine.

[21]  John Hoey,et al.  Clinical trial registration: a statement from the International Committee of Medical Journal Editors. , 2004, JAMA.

[22]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[23]  E. Winer,et al.  Informing clinical trial participants about study results. , 2002, JAMA.

[24]  Kay Dickersin,et al.  Publication bias against negative results from clinical trials: three of the seven deadly sins , 2007, Nature Clinical Practice Neurology.

[25]  J. Avorn.  Dangerous deception--hiding the evidence of adverse drug effects. , 2006, The New England journal of medicine.

[26]  Nicholas C. Ide,et al.  Trial Registration at ClinicalTrials.gov between May and October 2005. , 2005, The New England journal of medicine.

[27]  I. Sim,et al.  Clinical trial registration: transparency is the watchword , 2006, The Lancet.

[28]  W. Hiatt.  Observational studies of drug safety--aprotinin and the absence of transparency. , 2006, The New England journal of medicine.

[29]  H. Krumholz,et al.  What have we learnt from Vioxx? , 2007, BMJ : British Medical Journal.

[30]  J. Avorn.  In defense of pharmacoepidemiology--embracing the yin and yang of drug research. , 2007, The New England journal of medicine.